“Healthcare is changing all over the world, and these changes are opening up great opportunities for providers, for patients—and for our company,” said Michael Sen, member of the managing board of Siemens AG and Siemens Healthcare GmbH supervisory board chairman. “Today, we provide more than 10 billion laboratory diagnostics tests each year. Our mission is to extend this reach even further and Walpole will play a major role in this effort.”

“Siemens has been doing business in the United States for more than 160 years. We not only deliver products and solutions to America, but the Walpole expansion demonstrates our passion for making things here, hiring here and working closely with U.S. customers,” said Lisa Davis, chair and CEO of Siemens Corp. and member of the managing board of Siemens AG. “By investing in advanced manufacturing right here in the U.S., Siemens creates value for customers and communities, produces high-wage jobs, increases exports and creates more orders for local businesses of all sizes.”

Siemens held a groundbreaking ceremony for the project last Friday. Among the dignitaries that attended the event included Massachusetts Gov. Charlie Baker, who noted, “Our administration has reinforced our commitment to life sciences, research and development by investing up to $500 million for strategic investments to support companies in innovation and technology. Thanks to companies like Siemens, Massachusetts continues to be a global leader in the industry and we welcome their growth and investment in Walpole to support the global healthcare market.”

On June 19, Gov. Baker announced the state would provide up to $500 million over five years for strategic investments in public infrastructure, research and development, workforce training and education, including up to $295 million in capital authorization and up to $150 million job-creating tax incentive for the life sciences sector. The funding will continue to be managed by the Massachusetts Life Sciences Center.

Gov. Baker addressed the 2017 BIO International Convention in San Diego on June 21 and reinforced the administration's commitment to the Commonwealth's leadership in the growing life sciences sector. The next BIO International Convention will be held in Boston in June 2018.

WALPOLE, MA—Global technology company Siemens has begun construction on a major expansion of its manufacturing and R&D laboratory diagnostics facility here.

Siemens reports that the $300-million investment will create up to 700 new high-tech jobs over the next 10 years at the Walpole site. Siemens Healthineeers announced it would move forward with the expansion project last December.

The Walpole facility currently employs more than 700 employees and is the main manufacturing facility for assays that run on the Advia Centaur family of immunoassay instruments and for consumables for its molecular and blood gas testing instruments, the company reports. When completed, the facility will also manufacture assays to run on the immunoassay module of the Atellica Solution1, which is currently in development.

Siemens and its separately managed healthcare company Siemens Healthineers, when they announced plans for the Walpole site in late 2016, said they intend to upgrade and expand the existing 500,000-square-foot complex. The expansion will include new manufacturing, warehouse, office and lab space. Total employment at the site is expected to be between 1,300 and 1,600 by 2026.

“Healthcare is changing all over the world, and these changes are opening up great opportunities for providers, for patients—and for our company,” said Michael Sen, member of the managing board of Siemens AG and Siemens Healthcare GmbH supervisory board chairman. “Today, we provide more than 10 billion laboratory diagnostics tests each year. Our mission is to extend this reach even further and Walpole will play a major role in this effort.”

“Siemens has been doing business in the United States for more than 160 years. We not only deliver products and solutions to America, but the Walpole expansion demonstrates our passion for making things here, hiring here and working closely with U.S. customers,” said Lisa Davis, chair and CEO of Siemens Corp. and member of the managing board of Siemens AG. “By investing in advanced manufacturing right here in the U.S., Siemens creates value for customers and communities, produces high-wage jobs, increases exports and creates more orders for local businesses of all sizes.”

Siemens held a groundbreaking ceremony for the project last Friday. Among the dignitaries that attended the event included Massachusetts Gov. Charlie Baker, who noted, “Our administration has reinforced our commitment to life sciences, research and development by investing up to $500 million for strategic investments to support companies in innovation and technology. Thanks to companies like Siemens, Massachusetts continues to be a global leader in the industry and we welcome their growth and investment in Walpole to support the global healthcare market.”

On June 19, Gov. Baker announced the state would provide up to $500 million over five years for strategic investments in public infrastructure, research and development, workforce training and education, including up to $295 million in capital authorization and up to $150 million job-creating tax incentive for the life sciences sector. The funding will continue to be managed by the Massachusetts Life Sciences Center.

Gov. Baker addressed the 2017 BIO International Convention in San Diego on June 21 and reinforced the administration's commitment to the Commonwealth's leadership in the growing life sciences sector. The next BIO International Convention will be held in Boston in June 2018.